People who don't have insurance can continue to go to and immediately download the Lilly Insulin Value Program savings card to receive Lilly insulins for $35 per month.Effective immediately, Lilly will automatically cap out-of-pocket costs at $35 at participating retail pharmacies for people with commercial insurance using Lilly insulin.In addition to reducing the list price of its insulins, Lilly is making it easier for more people with diabetes to get Lilly insulins: Because these price cuts will take time for the insurance and pharmacy system to implement, we are taking the additional step to immediately cap out-of-pocket costs for patients who use Lilly insulin and are not covered by the recent Medicare Part D cap.'

'The aggressive price cuts we're announcing today should make a real difference for Americans with diabetes. 'While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change,' said David A.

Launching Rezvoglar TM (insulin glargine-aglr) injection, a basal insulin that is biosimilar to, and interchangeable with, Lantus ® (insulin glargine) injection, for $92 per five pack of KwikPens ®, a 78% discount to Lantus, effective April 1, 2023.

Cutting the list price of Humalog ® (insulin lispro injection) 100 units/mL 1, Lilly's most commonly prescribed insulin, and Humulin ® (insulin human) injection 100 units/mL 2 by 70%, effective in Q4 2023.

Effective May 1, 2023, it will be the lowest list-priced mealtime insulin available, and less than the price of a Humalog ® vial in 1999.

Cutting the list price of its non-branded insulin, Insulin Lispro Injection 100 units/mL, to $25 a vial.

Today, Lilly is reducing the list price of insulins by: Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable insulin. INDIANAPOLIS, Ma/PRNewswire/ - Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month.

Download xtreme flip n out prices